Collectively therefore, these proposals appear to argue for the terms ‘Alzheimer’s continuum’, ‘Alzheimer’s Disease’ or ‘at-risk for Alzheimer’s’ being used only when Aβ (and, in the case of the IWG, tau) pathology is detected, irrespective of a clinical diagnosis or age. This evidence concerns the gene MAPT and Alzheimer disease.